Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

CLRB

CLRB News

Newswire

17:18

Cellectar shares surge 13.36% after hours on FDA rare disease designation for iopofosine I-131 and clinical progress.

14:30

Cellectar shares surge 12.05% intraday following FDA Rare Pediatric Disease designation for iopofosine I-131 and positive clinical data from CLOVER-2 trial.

16:09

Cellectar Biosciences Advances Global Regulatory Strategy, Raises $12.7M, and Pursues Strategic Partnerships

09:56

Cellectar Biosciences Q3 net loss narrows to $4.4 mln.

07:24

Cellectar Seeks EU Approval for Iopofosine in Waldenstrom's Macroglobulinemia.

View More

About CLRB

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More